Bristol Myers Squibb Offers Growth With A Safe Dividend

About: Bristol-Myers Squibb Company (BMY)
by: William Meyers
This article is exclusive for subscribers.
William Meyers
Long only, tech, biotech, research analyst

The acquisition of Celgene expanded the Bristol Myers pipeline.

Revenue growth will continue despite some patent expirations.

The dividend is safe and likely to be increased.

Bristol Myers Squibb (BMY) is one of the world's largest pharmaceutical companies, with a current market cap of about $123 billion and annual sales running over $40 billion. It generates strong cash flow